Effects of oxidant balance on colon and breast cancer

描述（由申请人提供）： 主要的主题思想，局部和全身氧化剂的平衡是一个关键 结肠癌发生、进展和转移转化的决定因素 和乳腺癌调节局部和全身氧化剂平衡的潜力 将进行研究，以确定遗传和功能 癌症进展的后果。选择性癌症模型， 适当定义原位转化、增殖、侵袭和 转移将与遗传和功能分析结合使用， 明确定义癌症进展中的这些事件。该计划的一部分将是 旨在确定饮食诱导的癌症基因表达变化， 对应于癌症进展途径中的特定步骤。具体 基因调节事件可以被描述为以下的正效应物或负效应物： 肿瘤发生、侵袭或转移。可再现的基因表达变化 在肿瘤细胞或宿主中观察到，并且可以与促癌细胞增殖或 抗氧化状态，然后将进一步发展为独立的生物标志物 氧化剂平衡依赖性肿瘤发生事件。氧化状态的生物标志物 以在肿瘤部位建立基线氧化剂平衡 在整个过程中， 每个肿瘤进展模型的过程。饮食干预将是 用作促氧化剂和抗氧化剂处理，以确定其贡献 或改变所观察到的氧化剂平衡水平和 相应的肿瘤进展事件总体的图解方法将 必须定义特定的积极和消极事件， 膳食成分，特别是那些影响局部或整体氧化剂 平衡，将有选择的致瘤事件。氧化剂的应用 然后将这些模型中定义的生物标志物筛选方法应用于 人肿瘤（即局部氧化剂平衡）以及循环血清水平 将与肿瘤状态和诊断相关。因此，一个长期目标是 这项合作将确定人体的基线氧化状态， 患者取决于他们的肿瘤类型，目前的治疗，饮食和生活方式 因素此外，在整个过程中持续进行氧化剂平衡监测 治疗方法，如化疗和放疗，新的治疗方法和变化 在饮食中的生活方式，可以采用的是添加剂的长期目标， 程序.

DESCRIPTION (provided by applicant): The primary thematic idea that the local and systemic oxidant balance is a key determinant for the initiation, progression and metastatic conversion of colon and breast cancers. Potential to modulate local and systemic oxidant balance with diet will be investigated to determine the genetic and functional consequences for cancer progression. Selective cancer models which appropriately define in situ transformation, proliferation, invasion and metastasis will be used in conjunction with genetic and functional analyses to clearly define these events in cancer progression. Part of the program will be directed towards defming diet-induced changes in cancer gene expression that correspond to particular steps in the cancer progression pathway. Specific gene regulating events may be delineated as positive or negative effecters of tumorigenesis, invasion or metastasis. Reproducible gene expression changes observed in tumor cells or the host and can be correlated to pro- or anti-oxidant status, will then be further developed as independent biomarkers of oxidant balance-dependent tumorigenic events. Biomarkers of oxidant status will be determined to establish baseline oxidant balance at the site of tumor initiation and progression as well as in the circulation over the entire time course of each tumor progression model. Dietary interventions will be employed as pro- and anti-oxidant treatments to determine their contribution or alteration to both the level of oxidant balance observed and the corresponding tumor progression events. The overall programatic approach will necessarily define the particular positive and negative events for which dietary constituents, especially those that affect local or overall oxidant balance, will have on select tumorigenic events. Application of oxidant biomarker screening methods defined in these models will then be applied to human tumors (i.e. local oxidant balance), as well as circulating serum levels will be correlated to tumor status and diagnosis. Thus, a long-term goal of this collaboration will be to define baseline oxidant status for human patients depending on their tumor type, current treatment, diet and lifestyle factors. In addition, continued oxidant balance monitoring through the course of treatments, such as chemo and radiotherapies, new therapeutics and changes in diet in lifestyle which may be employed are additive long term goals of the program.